AHSCT
A triplet treatment plus autologous stem-cell transplantation was associated with longer progression...
The data were from the phase III DETERMINATION trial...
Carfilzomib, lenalidomide, and dexamethasone improved progression-free survival (PFS) over...
Advertisement
In second-line therapy for relapsed/refractory LBCL, which patients would you consider eligible for CAR T-cell therapy...
The CAR T-cell therapy received accelerated approval for adults with R/R FL after two or more lines of systemic therapy.
Patients with newly diagnosed primary central nervous system lymphoma who received high-dose chemotherapy and autologous ...
Advertisement
The European Medicines Agency validated a type II variation for the extension of the indication for lisocabtagene maraleucel ...
In patients with newly diagnosed MM, the addition of AHSCT to a triplet regimen of lenalidomide, bortezomib, and ...
Clinicians who specialize in BPDCN discuss the disease and novel therapeutic approaches to treating patients with BPCDN.
Autologous hematopoietic stem cell transplantation improved survival outcomes for certain patients younger than 65.
Long-term lymphoma survivors who underwent transplant had impaired health-related quality of life.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.